Prostate cancer markers: An update (Review)
- Authors:
- Srinivas Pentyala
- Terry Whyard
- Sahana Pentyala
- John Muller
- John Pfail
- Sunjit Parmar
- Carlos G. Helguero
- Sardar Khan
-
Affiliations: Department of Anesthesiology, Stony Brook Medical Center, Stony Brook, NY 11794, USA, Department of Urology, Stony Brook Medical Center, Stony Brook, NY 11794, USA - Published online on: January 29, 2016 https://doi.org/10.3892/br.2016.586
- Pages: 263-268
This article is mentioned in:
Abstract
|
Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
American Cancer Society Report. Cancer Facts and Figures. 2015.http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015Accessed. November 08–2015 | |
|
Greenberg R: Does prostate cancer represent more than one cancer? Prostate Cancer: Science and Clinical Practice. Mydlo JH and Godec CJ: (San Diego, CA). Academic Press. 29–34. 2003. View Article : Google Scholar | |
|
Gohiji K and Kitazawa S: Molecular mechanism of prostate cancer invasion and metastasis. Prostate Cancer: Science and Clinical Practice. Mydlo JH and Godec CJ: (San Diego, CA). Academic Press. 11–27. 2003. View Article : Google Scholar | |
|
Gutman AB and Gutman EB: ‘Acid’ phosphatase occurring in serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest. 17:473–478. 1938. View Article : Google Scholar : PubMed/NCBI | |
|
Heller JE: Prostatic acid phosphatase: Its current clinical status. J Urol. 137:1091–1103. 1987.PubMed/NCBI | |
|
Bahnson RR and Catalona WJ: Adverse implications of acid phosphatase levels in the upper range of normal. J Urol. 137:427–430. 1987.PubMed/NCBI | |
|
Lowe FC and Trauzzi SJ: Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol Clin North Am. 20:589–595. 1993.PubMed/NCBI | |
|
Burnett AL, Chan DW, Brendler CB and Walsh PC: The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. J Urol. 148:1832–1834. 1992.PubMed/NCBI | |
|
Ablin RJ, Soanes WA, Bronson P and Witebsky E: Precipitating antigens of the normal human prostate. J Reprod Fertil. 22:573–574. 1970. View Article : Google Scholar : PubMed/NCBI | |
|
Wang MC, Valenzuela LA, Murphy GP and Chu TM: Purification of a human prostate specific antigen. Invest Urol. 17:159–163. 1979.PubMed/NCBI | |
|
Papsidero LD, Wang MC, Valenzuela LA, Murphy GP and Chu TM: A prostate antigen in sera of prostatic cancer patients. Cancer Res. 40:2428–2432. 1980.PubMed/NCBI | |
|
Robert M, Gibbs BF, Jacobson E and Gagnon C: Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry. 36:3811–3819. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS and Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 317:909–916. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Tchetgen MB and Oesterling JE: The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia. Urol Clin North Am. 22:333–344. 1995.PubMed/NCBI | |
|
Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL and Lange PH: Screening for prostatic carcinoma with prostate specific antigen. J Urol. 147:841–845. 1992.PubMed/NCBI | |
|
Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM and Ross CA: Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology. 46:863–869. 1993. | |
|
Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA and Mostofi FK: The Investigators of the American Cancer Society-National Prostate Cancer Detection Project: Characteristics of prostate cancers detected in a multimodality early detection program. Cancer. 72:1701–1708. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Catalona WJ, Smith DS, Ratliff TL and Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 270:948–954. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Babaian RJ and Camps JL: The role of prostate-specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy. Cancer. 68:2060–2063. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Oesterling JE, Brendler CB, Epstein JI, Kimball AW Jr and Walsh PC: Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol. 138:92–98. 1987.PubMed/NCBI | |
|
Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT and Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 277:1445–1451. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT, Montie JE, Pearson JD, Slezak JM and Zincke H: Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 164:1591–1595. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI and Pearson JD: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 58:843–848. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ellis DW, Leffers S, Davies JS and Ng AB: Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. Am J Clin Pathol. 81:279–284. 1984.PubMed/NCBI | |
|
Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP and Walsh PC: Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 143:747–752. 1990.PubMed/NCBI | |
|
Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, Pettersson K, Scardino PT, Hallmans G and Lilja H: Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: A nested case-control study. Eur Urol. 68:207–213. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yousef GM and Diamandis EP: The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev. 22:184–204. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1214–1220. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Partin AW, Catalona WJ, Finlay JA, Darte C, Tindall DJ, Young CY, Klee GG, Chan DW, Rittenhouse HG, Wolfert RL, et al: Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis. Urology. 54:839–845. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Haese A, Becker C, Noldus J, Graefen M, Huland E, Huland H and Lilja H: Human glandular kallikrein: 2 A potential serum marker for predicting the organ confined versus non organ confined growth of prostate cancer. J Urol. 163:1491–1497. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SW, Hosokawa K, Kim S, Jeong OC, Lilja H, Laurell T and Maeda M: Highly sensitive porpus silicon(P-Si)-based Human Kallikrein 2 (hK2) immunoassap platform toward accurate diagnosis of prostate cancer. Sens Basel. 15:11972–11987. 2015. View Article : Google Scholar | |
|
Yu H and Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 92:1472–1489. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Djavan B, Bursa B, Seitz C, Soeregi G, Remzi M, Basharkhah A, Wolfram R and Marberger M: Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology. 54:603–606. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Shariat SF, Bergamaschi F, Adler HL, Nguyen C, Kattan MW, Wheeler TM and Slawin KM: Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. Urology. 56:423–429. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM and Slawin KM: Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and −3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 20:833–841. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Blobe GC, Schiemann WP and Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med. 342:1350–1358. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Perry KT, Anthony CT and Steiner MS: Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate. Prostate. 33:133–140. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM and Slawin KM: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 19:2856–2864. 2001.PubMed/NCBI | |
|
Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT and Thompson TC: Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 161:182–187. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Perry KT, Anthony CT, Case T and Steiner MS: Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology. 49:151–155. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM and Slawin KM: Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 10:1992–1999. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Giri D, Ozen M and Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 159:2159–2165. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM and Slawin KM: Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 58:1008–1015. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W, et al: Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol. 12:2634–2639. 1994.PubMed/NCBI | |
|
Shariat SF, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM and Slawin KM: Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 62:5974–5979. 2002.PubMed/NCBI | |
|
Gregorakis AK, Holmes EH and Murphy GP: Prostate-specific membrane antigen: Current and future utility. Semin Urol Oncol. 16:2–12. 1998.PubMed/NCBI | |
|
Millon R, Jacqmin D, Muller D, Guillot J, Eber M and Abecassis J: Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: Clinical implications. Eur Urol. 36:278–285. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Epstein JI, Carmichael M and Partin AW: OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology. 45:81–86. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Shurbaji MS, Kalbfleisch JH and Thurmond TS: Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol. 27:917–921. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W and Verhoeven G: Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 98:19–22. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Masterson R and Getzenberg RH: Early identification of individuals with prostate cancer in negative biopsies. J Urol. 171:1419–1423. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Bolduc S, Lacombe L, Naud A, Grégoire M, Fradet Y and Tremblay RR: Urinary PSA: A potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J. 1:377–381. 2007.PubMed/NCBI | |
|
Woodson K, O'Reilly KJ, Hanson JC, Nelson D, Walk EL and Tangrea JA: The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol. 179:508–511; discussion 511–512. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, Blase A, Koo S, Sarno M, Rittenhouse H, et al: A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta. 389:1–6. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, et al: PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol. 179:1587–1592. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Neves AF, Araújo TG, Biase WK, Meola J, Alcântara TM, Freitas DG and Goulart LR: Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem. 41:1191–1198. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tinzl M, Marberger M, Horvath S and Chypre C: DD3PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer. Eur Urol. 46:182–186; discussion 187. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H and Babaian RJ: PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 179:1804–1810. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, et al: The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 13:939–943. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
van Gils MP, Hessels D, van de Hulsbergen-Kaa CA, Witjes JA, Jansen CF, Mulders PF, Rittenhouse HG and Schalken JA: Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate. 68:1215–1222. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB and Schalken JA: Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res. 13:5103–5108. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, et al: A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68:645–649. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H, Lavin MF and Gardiner RA: Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 114:950–956. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ronquist G and Nilsson BO: The Janus-faced nature of prostasomes. Their pluripotency favours the normal reproductive process and malignant prostate growth. Prostate Cancer Prostatic Dis. 7:21–31. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Delves GH, Stewart AB, Cooper AJ and Lwaleed BA: Prostasomes, angiogenesis, and tissue factor. Semin Thromb Hemost. 33:75–79. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Babiker AA, Hamad OA, Sanchez J, Ronquist G, Nilsson B and Ekdahl KN: Prothrombotic effect of prostasomes of metastatic cell and seminal origin. Prostate. 67:378–388. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chavarro JE, Stampfer MJ, Campos H, Kurth T, Willett WC and Ma J: A prospective study of trans-fatty acid levels in blood and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 17:95–101. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chavarro JE, Stampfer MJ, Li H, Campos H, Kurth T and Ma J: A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 16:1364–1370. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gann PH, Hennekens CH, Ma J, Longcope C and Stampfer MJ: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 88:1118–1126. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC and Giovannucci E: Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 14:1262–1269. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P and Giles GG: Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 15:86–91. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Prensner JR, Zhao S, Erho N, Schipper M, et al: RNA biomarkers associated with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 15:1469–1480. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Øverbye A, Skotland T, Koehler CJ, Thiede B, Seierstad T, Berge V, Sandvig K and Llorente A: Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget. 6:30357–30376. 2015.PubMed/NCBI |
